PPT-Hepatology

Case Conference By Soheil Altafi MD 022415 Case 49 AAF seen in H epatology clinic 2011 PMHx PSC dx 2005 in BR lung dz unknown etiology PSHx bl tubal ligation cholecystectomy. Urogynae Haematology Hepatology Nephrology Neurology Neurosurgery Ophthalmology Oral And Maxillofacial Surgery Orthopaedics Persistent Pain Respiratory Rheumatology Surgery Surgery Colorectal Urology Vascular Surgery Jan 2013 waiting list Current wa naturecomclinicalpracticegasthe How to critically appraise an article Jane M Young and Michael J Solomon INTRODUCTION To practice evidencebased medicine clinicians need to apply the findings of scientific research to the circumstances of individual p . + . Sofosbuvir. in Genotype . 3. ALLY-3 Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Nelson DR, . et al. . . Hepatology. 2015;61:1127-35.. Source: . Nelson DR, et al. . Chennai – 600 003. .. Chief Minister’s Comprehensive Health Insurance Scheme. History. GGH- started as a small hospital to treat sick soldiers of British east India company on 16. th. Nov 1664. N = 45. N = 49. W24. W16. MK3. > . 18 years. HCV infection. G. enotype 1. Relapse after LDV/SOF or EBR/GZR. Compensated . cirrhosis** . allowed. Well-controlled HIV co-infection allowed. Randomisation. . or 3 . LONESTAR-2. Phase 2. Treatment. . Experienced. Lawitz. . E, et al. . Hepatology. . 2015:61:769-75.. Source: . Lawitz. E, et al. . Hepatology. . . 2015:61:769-75.. Sofosbuvir + . PEG + RBV . Design. Objective. SVR. 12. (HCV RNA < 25 IU/ml) in genotype 1. DCV 60 mg . qd. + . SOF 400 mg . qd. + RBV. DCV 60 mg . qd. + . SOF 400 mg . qd. + RBV. Not . randomised. Open-label. ALLY-1 Study: DCV + SOF + RBV for advanced liver disease and post-liver transplant recurrence. Randomisation. 1 : 1. 18-70 years. HCV genotype 1. Naïve or pre-treated. with IFN-based regimen. No cirrhosis. HCV RNA ≥ . 10.000 . IU. /ml. No prior therapy with PI. No HBV or HIV co-infection. OPTIMIST-1 Study: SMV SOF for genotype 1. About these slides. These slides provide highlights of new data presented at the International Liver Congress 2018. Please feel free to use, adapt, and share these slides for your own personal use; however, please acknowledge EASL as the source. Moderator. Kris V. Kowdley, MD . Director . Liver Institute Northwest . Clinical Professor. Elson S. Floyd College of Medicine. Washington State University. Seattle, Washington . Overview of Discussion. 105 Reoviruswasassociatedwithbiliaryatresiawhentheviruscausedsimilarsignsandsymptomsinweaningmice.Later,Moreckietal.reportedahighprevalenceofpositiveserologicresultsforreovirusinpatientswithatresia,th AutoantibodyandHumanLeukocyteAntigenProfiles inChildrenWithAutoimmuneLiverDiseaseand TheirFirst-DegreeRelatives
PengyunWang, jj HaibinSu,
JamesUnderhill,
LauraJ.Blackmore,
MariaSer Received8February2018;accepted20April2018;https://doi.org/10.1016/j.ymthe.2018.04.018 1840MolecularTherapyVol.26No7July20182018TheAuthors.ThisisanopenaccessarticleundertheCCBY-NC-NDlicense(http://crea The revised fourth edition of Evidence-Based Gastroenterology and Hepatology continues to provide the most current, evidence-based information for determining the appropriate medical and surgical options for screening for, diagnosing, and treating gastrointestinal conditions. With contributions from an international team of leading experts in the field, the 4th edition includes practical recommendations for the care of individual patients based on the latest scientific evidence.